Search Articles
Filter Articles
Open filtersClose filters
Sections
- All (3,729 articles)
- Pharma Events (46 articles)
- For Recruiters (272 articles)
- Careers Events (7 articles)
- Partners (3 articles)
- News (3,117 articles)
- Careers Advice (295 articles)
- Company Focus (193 articles)
- Company Career Hubs (1 article)
- Pharma Training (7 articles)
- 25 Years of PharmiWeb (13 articles)
- DE&I (3 articles)
Found 3,729 articles
ABPI welcomes the appointment of new MHRA Chair
- 20 Nov 2024
Anthony Harnden has been appointed the new chair of the Medicine and Healthcare products Regulatory Agency.
Abbott Unveils New Recommendations and Partnerships to Improve Diversity in Clinical Trials
- 20 Nov 2024
Abbott today announced that, in the third year of its multi-million-dollar Diversity in Clinical Trials initiative, the company has published 'Advancing Diversity in Clinical Trials' to share strategies to make clinical research and the teams leading these trials more diverse across the U.S. Concurrently, Abbott also revealed new partnerships to continue driving diversity in clinical trials by breaking down traditional barriers to care.
Is a Cover Letter Ever Really Optional?
- 19 Nov 2024
According to a study by Resume Genius, 78% of recruiters and hiring managers in the US prefer applicants to submit a cover letter, with 25% of this group indicating that it was very important when deciding which applicants to interview. Only 6% said cover letters were not at all important.
Late-Breaking Data Reinforce Long-Term Benefits of Abbott's Amplatzer™ Amulet™ Device for People With Atrial Fibrillation at Risk of Stroke
- 19 Nov 2024
Abbott today announced late-breaking data for the Amplatzer™ Amulet™ Left Atrial Appendage (LAA) Occluder to treat people with atrial fibrillation (AFib) who are at an increased risk of stroke.
Abbott Opens State-of-the-Art Global Manufacturing Facility in Kilkenny, Ireland
- 19 Nov 2024
Abbott today marked the official opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland with a ceremony attended by An Taoiseach, Simon Harris, TD, and Abbott Chairman and Chief Executive Officer, Robert Ford. The site is a global manufacturing center of excellence for Abbott’s diabetes care business and will employ more than 800 people.
-
Lilly's muvalaplin lowered lipoprotein(a) levels in adults with high risk for cardiovascular events by up to 85% at highest tested dose
- 19 Nov 2024
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for muvalaplin, an investigational once-daily, orally administered selective inhibitor of lipoprotein(a) [Lp(a)], a genetically inherited risk factor for heart disease.
Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC)
- 19 Nov 2024
GSK plc (LSE/NYSE: GSK) today announced positive headline results of GLISTEN, the ongoing global phase III clinical trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter (IBAT), in adults with cholestatic pruritus (relentless itch) associated with primary biliary cholangitis (PBC), a rare autoimmune liver disease.
Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
- 19 Nov 2024
UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE).
Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
- 19 Nov 2024
Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has approved OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea1,2 (aflibercept), developed and registered by Samsung Bioepis.
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
- 18 Nov 2024
Boston Scientific Corporation (NYSE: BSX) today announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MPM)
- 18 Nov 2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with pemetrexed and platinum chemotherapy, for the first-line treatment of adult patients with unresectable non-epithelioid malignant pleural mesothelioma (MPM).
AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
- 18 Nov 2024
AbbVie (NYSE: ABBV) today announced the European Commission (EC) granted marketing authorization for ELAHERE® (mirvetuximab soravtansine) for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three prior systemic treatment regimens.
Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer
- 18 Nov 2024
AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations and whose disease has not progressed during or following platinum-based chemoradiation therapy (CRT).
Stryker launches next generation of SurgiCount+ to help improve the standard of care in hospitals for sponge management and blood loss assessment
- 18 Nov 2024
Stryker (NYSE:SYK), a global leader in medical technologies, announced its launch of the next generation of SurgiCount+ within its sponge management portfolio. Now integrated with Stryker’s Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment.
Rippon Ubhi appointed Chair of the European Medicines Group
- 15 Nov 2024
Sanofi today announced that Rippon Ubhi has been appointed as the new Chair of the European Medicines Group (EMG). Rippon will continue her role as Country Lead for Sanofi UK & Ireland alongside this new appointment.
Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd
- 15 Nov 2024
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today announced that Merck has entered into an exclusive global license to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova.
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations
- 15 Nov 2024
AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest designed to support the career aspirations of people living with migraine.
Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
- 15 Nov 2024
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
- 15 Nov 2024
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
pobl. welcomes Lindsey Heer as Partner, Talent Strategy, elevating expertise in Medical Communications and Life Sciences
- 14 Nov 2024
Talent consulting start-up, pobl., is thrilled to announce the addition of Lindsey Heer to its team. Lindsey, an experienced leader in medical communications, with foundations in the pharmaceutical industry, joins pobl. alongside founder Tom Davies
